MASLD Creates a Portal Hypertension Problem Standard Testing Does Not Fully Solve
Portal hypertension remains the main hemodynamic engine of decompensation in advanced chronic liver disease, but metabolic dysfunction-associated steatotic liver disease does not always follow the classic sinusoidal pattern seen in viral cirrhosis. In MASLD, portal pressure can arise from a mixed sinusoidal-presinusoidal phenotype, and clinical deterioration may appear at lower hepatic venous pressure gradient values than clinicians have come to expect from older disease models. In practical terms, a patient can look congested from a portal standpoint while HVPG still appears less dramatic than the bedside picture suggests.
The diagnostic problem is amplified by obesity. Liver stiffness measurement by vibration-controlled transient elastography, FIB-4, ANTICIPATE-NASH, spleen stiffness, and the NICER model all retain some discriminatory ability, yet obesity degrades their performance through technical limitations and altered thresholds. The result is not simply imperfect accuracy; it is a meaningful zone of uncertainty in which noninvasive testing may fail to rule in clinically significant portal hypertension with the confidence needed to guide management. In obese MASLD, no noninvasive rule-in strategy reaches a 90% positive predictive value, leaving clinicians to make decisions with incomplete hemodynamic clarity.
Portal pressure is not just a number. In MASLD, it becomes a moving target shaped by body habitus, fibrosis distribution, and the presinusoidal component of disease that can blunt the apparent relationship between HVPG and actual portal stress.
Why Endohepatology Fits the Biology of Metabolic Liver Disease
Endohepatology is being positioned as a response to those blind spots. The approach brings hemodynamic, elastographic, and histologic assessment into a single sedated session, giving clinicians several kinds of data at once rather than forcing them to assemble a partial picture from separate tests. EUS-guided shear-wave elastography and EUS-guided liver biopsy can clarify whether fibrosis has reached the F2-F3 range when treatment eligibility is uncertain. EUS-guided portal pressure gradient measurement can provide a direct gradient when HVPG or noninvasive tests conflict with the clinical phenotype. EUS-based vascular assessment can also map collateral circulation and variceal anatomy.
The appeal of the platform is biological as much as technical. MASLD often presents with metabolic inflammation, obesity, and heterogeneous fibrosis that make indirect markers less dependable. Endoscopic ultrasound can bypass some of the acoustic and body-habitus constraints that weaken transabdominal imaging, while direct portal pressure measurement can probe the hemodynamic consequence of disease rather than infer it indirectly. In a disorder where portal hypertension may emerge before the textbook sinusoidal pattern is fully established, that distinction is clinically important.
A single session can answer three different questions: how much fibrosis is present, how severe the portal pressure burden is, and whether collateral vessels are already forming.
Pressure, Fibrosis, and Varices Can Be Adjudicated in One Session
This integrated pathway has obvious value when the phenotype and the test results do not match. A patient with MASLD, obesity, and signs suggestive of portal hypertension may have a liver stiffness result that is hard to interpret, a serum score that sits in the gray zone, and an HVPG value that seems lower than the overall clinical impression. Endohepatology offers a way to reconcile those mismatched signals without sending the patient through multiple separate procedures.
That matters because management decisions in MASLD are often threshold dependent. Fibrosis stage can influence treatment eligibility, portal pressure can influence surveillance and prophylaxis strategy, and the presence of varices or collaterals changes the risk conversation immediately. EUS-guided liver biopsy adds histology when noninvasive methods cannot confidently separate F2 from F3 disease. EUS-guided portal pressure gradient assessment can clarify whether portal hypertension is truly present and how severe it is. EUS vascular evaluation can identify variceal anatomy that may be relevant to procedural planning or prophylactic treatment.
The same platform also extends to therapy. EUS-guided gastric variceal obliteration is included among the applications described, and the platform may be used in pre-bariatric risk stratification. In a patient population where obesity both drives liver injury and impairs diagnostic testing, the ability to evaluate the liver and intervene endoscopically in one setting has a direct bedside logic.
Early-Phase Data Support Utility, But Prospective Validation Is Still Needed
Current evidence remains early phase. The field has not yet reached the point where endohepatology can replace established tools outright, and the paper is explicit that prospective validation is still required. The technology should be viewed as complementary rather than substitutive, especially because established noninvasive tests still provide useful information in many patients and remain easier to deploy at scale.
Even so, the clinical niche is clear. MASLD is precisely the setting in which obesity, heterogenous fibrosis, and mixed portal hypertensive physiology make traditional pathways less dependable. When noninvasive markers degrade and HVPG seems discordant with the phenotype, endohepatology can supply a more complete physiologic assessment. The added value is strongest where the stakes are highest: deciding whether portal hypertension is truly clinically significant, whether fibrosis has reached a treatment-relevant threshold, and whether variceal anatomy demands direct action.
This is an integrated diagnostic and therapeutic framework built for the failures of fragmentation. Rather than asking one imperfect test to carry the whole burden, endohepatology combines pressure measurement, elastography, histology, and vascular assessment in a single procedure. In MASLD, where the disease biology itself frequently blurs conventional cutoffs, that kind of consolidation may prove more useful than any single standalone metric — but the current evidence base is still too early to define how often it should be deployed, in whom it should be preferred, and how it performs against established pathways in prospective comparative studies.